|
Dr. Moos has been Chairman and CEO of MitoKor, Inc. since 1997. From 1991 to 1997, he was employed at Chiron Corp., where he was an executive officer and last held the position of Vice President of R&D in the Technologies Division. From 1982 to 1991, Dr. Moos held several positions at the Parke-Davis Pharmaceutical Research Division of the Warner-Lambert Co., last holding the position of Vice President, Neuroscience and Biological Chemistry. In addition to serving as Chairman of the MitoKor Board of Directors, Dr. Moos currently serves on the Boards of Directors of Alnis, Anterion, Oncologic, Rigel Pharmaceuticals, Inc. and the Keystone Symposia, and has previously served on the Boards of Directors of Axiom Biotechnologies, the Biotechnology Industry Organization, CMPS, Mimotopes and Onyx Pharmaceuticals, Inc. He has edited several books, helped to found multiple journals, and has published over 100 manuscripts and patents. In addition, Dr. Moos has held adjunct faculty positions at the University of Michigan and the University of California, San Francisco, and currently serves on several academic and related advisory committees. Dr. Moos holds an AB from Harvard University and received his PhD in chemistry from the University of California, Berkeley, in 1982. Mr. Zuga developed a relationship with Dr. Moos in 2000, when Legg Mason was engaged to provide investment banking services to MitoKor, Inc. Mr. Zuga has advised the company on a number of transactions, including a potential IPO and various mergers and acquisitions. | 